Andrew Bagg, MD
Allergy & Immunology · Altamonte Springs, FLNPI 1962588053
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $81,936 of the $113,008 with a category attached, or 72.5%. 38 manufacturers reported payments, led by AstraZeneca at 45.5% of the total. Among allergy & immunology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 830 payments — averaging $136.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$51K
- GSK$27K
- Regeneron Healthcare Solutions, Inc.$11K
- CSL Behring$7K
- ARS Pharmaceuticals Operations, Inc.$3K
- Biocryst US Sales Co., LLC$3K
- plus $11K from 32 others
What the payments were for
- Consulting fees$7,6457%
- Speaking & faculty fees$81,93673%
- Travel & lodging$4,1094%
- Food & beverage$19,04217%
- Education$2750%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 181 | $51,380 |
| GSK | 138 | $26,800 |
| Regeneron Healthcare Solutions, Inc. | 57 | $10,872 |
| CSL Behring | 71 | $7,319 |
| ARS Pharmaceuticals Operations, Inc. | 10 | $3,142 |
| Biocryst US Sales Co., LLC | 99 | $2,876 |
| Pharming Healthcare, Inc. | 13 | $2,504 |
| Takeda Pharmaceuticals U.S.A., Inc. | 78 | $1,760 |
| Biocryst Pharmaceuticals, Inc. | 1 | $1,125 |
| Sanofi | 16 | $1,063 |
| Pfizer | 32 | $624 |
| Novartis | 19 | $513 |
| Aimmune Therapeutics, Inc. | 6 | $461 |
| Optinose US, Inc. | 20 | $442 |
| Genentech USA, Inc. | 10 | $321 |
| Grifols USA, LLC | 9 | $203 |
| Amgen | 8 | $199 |
| Alk-abello, Inc | 4 | $177 |
| Blueprint Medicines Corporation | 8 | $163 |
| Octapharma USA, Inc. | 2 | $122 |
| Boehringer Ingelheim | 6 | $114 |
| Covis Pharma GmbH | 5 | $98 |
| Kaleo, Inc. | 5 | $95 |
| AbbVie | 4 | $94 |
| Shire North American Group Inc | 4 | $83 |
| Ionis Pharmaceuticals, Inc. | 3 | $78 |
| GC Biopharma USA, Inc. | 3 | $65 |
| Teva Pharmaceuticals USA, Inc. | 3 | $56 |
| Galderma Laboratories, L.p. | 2 | $52 |
| Bio Products Laboratory USA, Inc. | 5 | $42 |
| ADMA Biomanufacturing LLC | 1 | $30 |
| Organon | 1 | $29 |
| LEO Pharma Inc. | 1 | $27 |
| Sunovion Pharmaceuticals Inc. | 1 | $22 |
| Merck | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Hikma Pharmaceuticals USA | 1 | $14 |
| Phadia US Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$113,008 in reported general payments places this provider in the 90th percentile of 204 allergy & immunology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TakhzyroLanadelumab-Flyo | 11 | $531,405 |
| XolairOmalizumab | 83 | $281,748 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 178 | $130,658 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 17 | $106,184 |
| Breo ElliptaFluticasone/Vilanterol | 90 | $53,164 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 22 | $17,185 |
| SymbicortBudesonide/Formoterol Fumarate | 52 | $15,794 |
| Arnuity ElliptaFluticasone Furoate | 53 | $13,299 |
| Spiriva RespimatTiotropium Bromide | 11 | $12,669 |
| Advair HfaFluticasone Propion/Salmeterol | 23 | $9,792 |
| Epinephrine | 41 | $7,817 |
| Qvar RedihalerBeclomethasone Dipropionate | 19 | $6,356 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 192 | $5,736 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 31 | $5,251 |
| Azelastine Hcl | 115 | $5,171 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Takhzyro | $1,760 | $531,40511 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $26,800 | $197,121321 claims |
| CSL BehringPrivigen | $7,319 | $106,18417 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $51,380 | $32,97874 claims |
| Boehringer IngelheimSpiriva Respimat | $114 | $12,66911 claims |
| Hikma Pharmaceuticals USAEpinephrine | $14 | $7,81741 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $56 | $6,35619 claims |
| MerckAsmanex | $17 | $1,52813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 204 allergy & immunology providers in Florida.
Other allergy & immunology in Altamonte Springs
- Pragnesh PatelAltamonte Springs$84K
- Warit JithpratuckAltamonte Springs$24K
- Jose Arias JrAltamonte Springs$14K
- Dennis LedfordTampa$1.2M
- Nina RamirezMiami$833K
- Thomas WestbrookPensacola$810K
- Shahnaz FattehPlantation$677K
- Thomas CasaleTampa$382K
- Thomas JohnsonGainesville$361K
- Mark GlaumTampa$337K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.